聚乙二醇干扰素α-2a治疗慢性乙肝患者对其ALT、HBV DNA载量的影响分析

摘要

Objective To study the impact of pegylated interferon α-2a on the load of ALT, HBV DNA in treating patients with chronic hepatitis B (CHB). Methods 60 CHB patients treated in our hospital from June 2012 to June 2014 were selected and randomly divided into observation group (33 cases) and control group (27 cases). The observation group was treated with pegylated interferonα-2a, the control group was treated with recombinant human interferonα-2a. The ALT recovery rate, adverse events rate, reduction of HBV DNA load and negative conversion rate of HBV DNA after 24 weeks and 48 weeks between two groups were compared. Results In observation group, the ALT recovery rate at 24 weeks and 48 weeks were 66.7%and 87.9%respectively, higher than 40.7%and 66.7%in control group, with statistical difference (P<0.05);the adverse events rate were 6.1%and 9.1%respectively, lower than 25.6%and 29.6%in control group, with statistical difference (P<0.05);the rate of HBV DNA load reduction>3 lg copy/mL were 75.8%and 87.9%respectively, higher than 48.1%and 66.7% in control group, with statistical difference (P <0.05); the negative conversion rate of HBV DNA were 66.7% and 78.8%respectively, higher than 37.0%and 51.8%in control group, with statistical difference (P<0.05). Conclusions Pegylated interferonα-2a can effectively inhibit the replication of HBV in treating patients with chronic hepatitis B, reduce the load of HBV DNA and level of ALT, continue to play anti-inflammation effect, which has significant value and deserves promotion.%目的：探析聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者对其ALT、 HBV DNA载量所造成的影响。方法选择我院2012年6月至2014年6月收治的慢性乙型肝炎患者60例，将其随机分为观察组(33例)和对照组(27例)，观察组应用聚乙二醇干扰素α-2a进行治疗，对照组应用重组人干扰素α-2a进行治疗。比较两组患者治疗后24周、48周时的ALT复常率、不良事件发生率、 HBV DNA载量下降幅度与HBV DNA阴转率。结果观察组患者24周以及48周的ALT复常率分别为66.7%和87.9%，高于对照组的40.7%和66.7%，差异有统计学意义(P<0.05)；观察组患者24周以及48周的不良事件发生率分别为6.1%和9.1%，均低于对照组的25.9%和29.6%，差异有统计学意义(P<0.05)；观察组24周与48周时，患者HBV DNA载量下降幅度超过3 lg拷贝/mL分别占75.8%和87.9%，显著高于对照组的48.1%和66.7%，差异有统计学意义(P<0.05)；观察组24周与48周的HBV DNA阴转率分别为66.7%和78.8%，显著高于对照组的37.0%和51.8%，差异有统计学意义(P<0.05)。结论应用聚乙二醇化干扰素α-2a治疗慢性乙型肝炎可有效抑制患者体内HBV病毒的复制，减少HBV DNA载量并降低ALT水平，持续发挥抗炎效果，应用价值大，值得推广。